Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Clinical Cardiology|October 12, 2002
Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival StudyFilippo Crea, Claudia Monaco, Gaetano A Lanza, et al.
Applied Clinical Informatics|February 20, 2020
Joint Design with Providers of Clinical Decision Support for Value-Based Advanced Shoulder ImagingMichael C Brunner, Scott E Sheehan, Eric M Yanke, et al.
Materials Science & Engineering. C, Materials for Biological Applications|October 27, 2021
The effect of erythrosine-B on the structuration of poloxamer 407 and cellulose derivative blends: In silico modelling supporting experimental studiesJéssica Bassi da Silva, Katieli da Silva Souza Campanholi, Gustavo Braga, et al.
AJNR. American Journal of Neuroradiology|August 11, 2005
Effects of carotid or vertebrobasilar stent placement on cerebral perfusion and cognitionRoham Moftakhar, Aquilla S Turk, David B Niemann, et al.
Epilepsia|October 30, 2009
Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trialsMichael R Sperling, Andrew Greenspan, Joyce A Cramer, et al.
New Forests|August 28, 2018
Plantation performance of chestnut hybrids and progenitors on reclaimed Appalachian surface minesJeff G Skousen, Kara Dallaire, Steffany Scagline-Mellor, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 25, 2017
Safety and efficacy of helminth treatment in relapsing-remitting multiple sclerosis: Results of the HINT 2 clinical trialJohn Fleming, Gianna Hernandez, Leslie Hartman, et al.
JAMA|March 27, 2007
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome TrialMarvin A Konstam, Mihai Gheorghiade, John C Burnett, et al.
JAMA|March 27, 2007
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status TrialsMihai Gheorghiade, Marvin A Konstam, John C Burnett, et al.
Heart Failure Reviews|September 21, 2011
A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trialMihai Gheorghiade, Peter S Pang, Andrew P Ambrosy, et al.
Pageof 10